LEADER 04930nam 2201237z- 450 001 9910557148103321 005 20231214133001.0 035 $a(CKB)5400000000040577 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68388 035 $a(EXLCZ)995400000000040577 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMetabolism and Metabolomics of Liver in Health and Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (268 p.) 311 $a3-03943-635-X 311 $a3-03943-636-8 330 $aWomen and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD. 606 $aMedicine$2bicssc 610 $anonalcoholic fatty liver disease 610 $anonalcoholic steatohepatitis 610 $aFibrosis 610 $aLiver biopsy 610 $aGenomics 610 $aMetabolomics 610 $aProteomics 610 $aTranscriptomics 610 $anicotinamide 610 $aNAFLD 610 $asteatosis 610 $aheat stress 610 $aprimary mouse hepatocytes 610 $ametabolic profile 610 $aGC-MS 610 $amultivariate statistical analysis 610 $aarachidonic acid 610 $adocosahexaenoic acid 610 $ainflammation 610 $afibrosis 610 $alipidomics 610 $amass spectrometry 610 $ain vitro 610 $aHepaRG 610 $asodium saccharin 610 $areference toxicants 610 $ade novo lipogenesis 610 $acarbohydrate response element-binding protein 610 $aChREBP 610 $adiabetes 610 $aglucose production 610 $aglycogen 610 $aglycolysis 610 $aglycogen storage disease type I 610 $ahexosamine 610 $apentose phosphate pathway 610 $aacupuncture 610 $aimflammation 610 $alipid metabolism 610 $aoxidative stress 610 $ametabolomics quantitative profiling 610 $a1H-NMR spectroscopy 610 $aliver 610 $abile acids 610 $ametabolomics 610 $arat plasma 610 $atandem mass spectrometry 610 $aliquid chromatography 610 $aacetaminophen 610 $ahepatotoxicity 610 $abiomarker 610 $apremalignant 610 $aalcoholic liver disease 610 $acholestasis 610 $acirrhosis 610 $aNAFL 610 $aNASH 610 $astandard operating procedures 610 $aurine 610 $ablood 610 $afeces 610 $atissue 610 $acells 610 $aliver function 610 $anonalcoholic fatty liver 610 $aliquid chromatography-mass spectrometry 610 $anuclear magnetic resonance spectroscopy 610 $ametabolic pathway 610 $anon-alcoholic fatty liver disease 610 $anon-alcoholic steatohepatitis 610 $atranscription factors 610 $ametabolic stress 610 $alipid homeostasis 610 $aglucose homeostasis 615 7$aMedicine 700 $aWahli$b Walter$4edt$01328658 702 $aGuillou$b Hervé$4edt 702 $aWahli$b Walter$4oth 702 $aGuillou$b Hervé$4oth 906 $aBOOK 912 $a9910557148103321 996 $aMetabolism and Metabolomics of Liver in Health and Disease$93038789 997 $aUNINA